ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

cadonilimab

Also written as “AK104”, “Cadonilimab” and “Cadonilimab (AK104)”.

Its studies are mostly in Carcinoma, Hepatocellular · Carcinoma, Non-Small-Cell Lung · Uterine Cervical Neoplasms · Carcinoma, Renal Cell · Stomach Neoplasms, led by 4 companies.

Drug pageCadonilimab: every studyAll 173 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jul 21, 202145 company-led studies, 22 open or runningNext primary completion: Nov 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Akesoits history only4219 open or runningphase 3since Jul 21, 2021Aug 20, 2017Nov 2026phase 3 · NCT06341335
RemeGenits history only11 open or runningphase 3since Jan 15, 2024Jan 15, 2024Dec 2026phase 3 · NCT06221748
Shanghai Pharmaceuticalsits history only11 open or runningphase 2since Jul 6, 2023Jul 6, 2023Dec 31, 2026phase 2 · NCT05944224
Summit Therapeutics11 open or runningphase 2since Sep 29, 2026Sep 29, 2026Apr 12, 2029phase 2 · NCT07877194

Also a collaborator on its studies: Chipscreen Biosciences.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Summit Therapeutics only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 19, 2020Named cadonilimabINNProposed as its International Nonproprietary Name in WHO's List 124 · before, AK104
  2. Sep 29, 2026First study: phase 2 study in Carcinoma, Renal CellFirst studyNCT07877194 · 100 planned · United States, China

Ahead

  1. Apr 12, 2029Primary completion: phase 2 study in Carcinoma, Renal CellNCT07877194

TargetBeta

CTLA4 →PDCD1 →read by rule
“A bispecific antibody directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), ”NCIt, by rule
“Programmed cell death protein 1 inhibitor; Cytotoxic T-lymphocyte protein 4 inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
Iparomlimab/TuvonralimabruleQilu Pharmaceuticalphase 322
volrustomigAstraZenecaphase 319
lorigerlimabruleMacroGenicsphase 24
Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010rulehc-biopharma-incphase 22

Studies

The one study Summit Therapeutics leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07877194Carcinoma, Renal Cell · United States, China2Not yet recruitingApr 12, 2029100

How it is read

Names in the registry

  • “AK104”, 26 entries
  • “Cadonilimab”, 3 entries
  • “Cadonilimab (AK104)”, 3 entries
  • “AK112, Cadonilimab, nab-paclitaxel, gemcitabine”, 3 entries
  • “AK104+anlotinib”, 3 entries

Codes read as this program: AK104.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.